Physician profile
Gitanjali Pai
NPI 1518197524
$6,545.03
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,011 · 2020: $35.06 · 2021: $16.22 · 2022: $434 · 2024: $49.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $49.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $49.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,476.61 | 2019 | |
| Merck Sharp & Dohme LLC | $288.76 | 2022 | |
| Astellas Pharma US INC | $237.99 | 2019 | |
| Gilead Sciences, INC. | $138.30 | 2019 | |
| Melinta Therapeutics, LLC | $76.71 | 2019 | |
| Shionogi INC | $76.19 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.60 | 2022 | |
| Janssen Products, Lp | $60.00 | 2019 | |
| Viiv Healthcare Company | $49.62 | 2024 | |
| Mylan Specialty L.P. | $22.50 | 2020 | |
| Seqirus USA INC | $20.97 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.22 | 2021 | |
| Lilly USA, LLC | $12.56 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gitanjali Pai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.